BRAF and melanoma: Patients with BRAF mutant melanomas treated with bevacizumab no longer exhibited significantly improved disease-free survival (HR 0.81 95% CI 0.60–1.10) nor overall survival (HR 0.80; 95% CI 0.57–1.13, p = 0.21) rates [36].